News/ News/ R&D Allergy Therapeutics suffers phase 3 birch allergy jab trial failure Richard Staines Allergy Therapeutics, birch allergy 0 Comment UK-based Allergy Therapeutics has suffered a setback after phase 3 results from the B301 trial of its latest Share X Allergy Therapeutics suffers phase 3 birch allergy jab trial failure https://pharmaphorum.com/news/allergy-therapeutics-suffers-phase-3-birch-allergy-jab-trial-failure/
R&D/ Top stories/ UK & Europe/ Views and analysis UK biotech round-up: Autolus joins CAR-T race, Horizon’s new CRISPR tech, Allergy Therapeutics’ grass gambit Andrew McConaghie Allergy Therapeutics, Autolous, CAR T, Horizon Discovery, UK biotech 0 Comment Three small, innovative firms demonstrate the diversity and promise of the UK bioscience sector. While there remains uncertainty Share X UK biotech round-up: Autolus joins CAR-T race, Horizon’s new CRISPR tech, Allergy Therapeutics’ grass gambit https://pharmaphorum.com/views-and-analysis/uk-biotech-roundup/
